Pitcairn’s Coherus Oncology CHRS Stock Holding History

Pitcairn’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-17,768	Closed	-$288K	–	504
2020 Q1	$288K	Buy	17,768 +4,821	+37%	+$89.1K	0.03%	308
2019 Q4	$233K	Buy	12,947 +1,086	+9%	+$20K	0.02%	480
2019 Q3	$240K	Buy	+11,861	New	+$237K	0.02%	466

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pitcairn's CHRS Position: Q2 2020 in Review

Pitcairn sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 17,768 shares — an estimated $288K sold.

Pitcairn first reported a position in CHRS in Q3 2019 and held it in 3 quarters. The position peaked at $288K in Q1 2020. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

Pitcairn reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
Pitcairn sold 17,768 Coherus Oncology shares in Q2 2020, an estimated $288K.
Pitcairn first reported a position in Coherus Oncology in Q3 2019 and held it in 3 quarters.
Pitcairn's Coherus Oncology position peaked at $288K in Q1 2020.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on Pitcairn's 13F filing for Q2 2020, filed 28 Jul 2020.